Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: The upregulated expression of BET proteins is closely associated with the occurrence and development of hematological malignancies and solid tumors. Several BET inhibitors have been developed, and some have been in phase I/II of clinical trials. Here, the safety, efficacy, and pharmacodynamics of ten BET inhibitors currently in clinical trials were evaluated. Methods: We retrieved and reviewed published reports on the clinical trials of twelve BET inhibitors including AZD5153, ABBV-075, BMS-986158, CPI-0610, GSK525762, OTX-015, PLX51107, INCB054329, INCB057643, FT-1101, CC-90010, and ODM-207 for patients with hematological malignancies and solid tumors and summarized their published target genes. Results: In the monotherapy of BET inhibitors, the most common and severe (grade ≥3) hematological adverse events (AEs) are thrombocytopenia, anemia, and neutropenia. The most common non-hematological syndromes are diarrhea, nausea, fatigue, dysgeusia, and decreased appetite, while the most severe AE is pneumonia. Additionally, Tmax of these BET inhibitors was between 0.5–6 h, but the range for T1/2 varied significantly. According to published data, the rates of SD, PD, CR and PR were 27.4%, 37.6%, 3.5%, and 5.7%, respectively, which is not very satisfactory. In addition to BRD4, oncogene MYC is another common target gene of these BET inhibitors. Ninety-seven signaling pathways may be regulated by BET inhibitors. Conclusion: All BET inhibitors reviewed in our study exhibited exposure-dependent thrombocytopenia, which may limit their clinical application. Moreover, further efforts are necessary to explore the optimal dosing schemes and combinations to maximize the efficacy of BET inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611
Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003) · ANZ Journal of Surgery · doi:10.1046/j.1445-2197.2003.02748.x · Cited by 7,603
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“Since the discovery of the first two BET inhibitors GSK525762 and JQ1 (Filippakopoulos et al., 2010; Nicodeme et al., 2010), a variety of new BET inhibitors have been developed.”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 5×
“BET inhibitor (target) Author Clinical trial registration number Phase Publication year Number of patients Study design Cancer type Median age (range) AZD5153 (BRD4) Wang et al. (2019) NCT03205176 1 2019 28 Single-arm R/R malignant solid tumor and lymphoma (n 28) 66.5 (no mention) ABBV-075 (BRD4) Piha-Paul et al. (201…”
BackgroundInfluentialStewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01341-10 · Cited by 532 · cited 2×
“BRD4 can recruit the PTEFb complex, JMJD6 (a histone arginine demethylase), NSD3 (a histone methyl transferase), P300 (acetyl transferase), and CHD4 (the catalytic subunit of the NuRD chromatin remodeler) (Taniguchi, 2016).”
BackgroundBET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463 · cited 1×
“Based on their diverse functions, BET proteins also participate in the occurrence and development of multiple tumors (Stathis and Bertoni, 2018).”
BackgroundHouzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., & Beddington, R. S. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3794-3802.2002 · Cited by 318 · cited 3×
“Unlike BRD2 and BRD3, aside from maintaining chromatin acetylation status, BRD4 can also regulate the transcription of growth-promoting genes through recruiting PTEFb (Houzelstein et al., 2002) or NSD3 (Rahman et al.”
BackgroundRole of p53/miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease
Wang, Y., Zheng, Z.-J., Jia, Y.-J., Yang, Y.-L., & Xue, Y.-M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1486-7 · Cited by 115
Cited by
Modulation of cellular processes by histone and non-histone protein acetylation
Shvedunova, M., & Akhtar, A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00441-y · Cited by 936
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Chen, J., Tang, P., Wang, Y., Wang, J., Yang, C., Li, Y., Yang, G., Wu, F., Zhang, J., & Ouyang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01835 · Cited by 62
The role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Metadata
- Authors
- Sun, Y., Han, J., Wang, Z., Li, X., Sun, Y., & Hu, Z.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-01-26
- Volume
- 11
- Pages
- 621093-621093
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3121733667
- Cited by
- 141
- References
- 10
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.